FDA green-lights second RET inhibitor, this time from Blueprint Medicines
The drug, Gavreto, or pralsetinib, won accelerated approval for RET fusion-positive non-small cell lung cancer, with or without prior therapy, while the FDA accepted the company's approval application for the drug in two types of thyroid cancer. The approval follows the May nod for Eli Lilly's Retevmo for all three indications.